olatorepatide vs THDBH120

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: GLP-1/GIP receptor (dual) · full Obesity pipeline

olatorepatide

Developed by Regeneron Pharmaceuticals under a licence from Hansoh Pharmaceutical Group

Phase 3 in Obesitypeptide
Reliable signal

NCT06839664 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial (n=604). The co-primary endpoints, percent weight change and the proportion achieving at least 5% weight loss at week 48, were both met: participants lost up to 19.3% of body weight and up to 97.2% achieved at least 5% weight loss, both significantly better than placebo.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: January 2028 · NCT07685808 (registry estimate)

Reported efficacy

Percent Change from Baseline in Body Weight (Baseline, week 48); Percentage of Participants Who Achieve weight loss≥ 5% from Baseline (Baseline, week 48): Co-primary endpoints met at Week 48: up to 19.3% mean weight loss with olatorepatide from baseline (dose range 5/10/15mg); up to 97.2% of participants achieved ≥5% weight loss, statistically significant vs placebo. (met)

Result source: NCT06839664

THDBH120

Developed by Tonghua Dongbao Pharmaceutical

Phase 2 in Obesitypeptide
Weak signal

NCT06951945 · Phase 1 · completed

The trial was randomized, double-blind, and placebo-controlled, which is a sound design. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Number of Participants with One or More Adverse Event(s) and Serious Adverse Event(s)". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Reported efficacy

Number of Participants with One or More Adverse Event(s) and Serious Adverse Event(s) (78 days): Phase Ib multiple-dose, randomized, double-blind, placebo-controlled study: THDBH120 led to weight loss of up to 9.36% at six weeks. The two lower-dosed regimens led to weight loss of 7.38% after four weeks and 8.03% after six. Three dosing regimens that involved increasing doses every two or four weeks all showed significance against placebo. (not_applicable)

Result source: NCT06951945

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointolatorepatideTHDBH120
Body weight, % change—Not posted · NCT06839664—Not reported
Weight loss of 5% or more—Not posted · NCT06839664—Not reported
Weight loss of 10% or more—Not posted · NCT06839664—Not reported
Waist circumference, change (cm)—Not posted · NCT06839664—Not reported

Body weight, % change

olatorepatide
—Not posted · NCT06839664
THDBH120
—Not reported

Weight loss of 5% or more

olatorepatide
—Not posted · NCT06839664
THDBH120
—Not reported

Weight loss of 10% or more

olatorepatide
—Not posted · NCT06839664
THDBH120
—Not reported

Waist circumference, change (cm)

olatorepatide
—Not posted · NCT06839664
THDBH120
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

THDBH120: no structured comparison results are available for Obesity.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

olatorepatide

Weight 19.3% @ 48wk
percent change · % of baseline
No placebo or comparator arm
NCT06839664 · Phase 3 · sponsor-reported, not registry data
Weight Loss 5% 97.2% @ 48wk
responder rate · % of participants
No placebo or comparator arm
NCT06839664 · Phase 3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: olatorepatide's landscape · THDBH120's landscape